Tablets-au.com Online ED Drugstore is an 1st. pharmacy providing a personal service to the society in Australia. Over 50,000 extremely satisfied buyers! We're your prescription drug store cialis australia and have provided trusted service to families in Australia for over 15 years.

Ors.umkc.edu2

Technology Available For License
Drug Delivery that Overcomes
P-glycoprotein Mediated Drug Efflux
A drug delivery system that overcomes the problems associated with P-glycoprotein mediated drug efflux. Disadvantages of Current Treatments:
P-Glycoprotein (P-gp) is a transport protein that effluxes a wide variety of structural y unrelated drugs out of cel s. The bioavailability of various anticancer drugs, anti-HIV drugs, calcium channel drugs, and other drugs which are substrates is limited by this efflux transporter. Over-expression of P-gp by tumor cel s confers multi-drug resistance. Efflux of many anticancer drugs including taxol, vincristine, vinblastine, actinomycin D, colchicines, and daunorubicin, from tumor cel s makes P-gp a major barrier to chemothera-py. High expression of this transporter on the blood-brain-barrier (BBB) restricts the entry into the brain of P-gp substrates such as anti-HIV drugs such as ritonavir, saquinavir, nelfinavir, and various anticancer drugs, and thus imposes a major chal enge in the treat-ment of various diseases of the brain. Expression of the efflux transporter on various body tissues and cel s not only influences the in vivo disposition of various therapeuti-cal y active drugs, but also greatly influences the drugs' pharmacokinetics. It has been known that inhibition of P-gp by various modulators can lead to improved bioavailability of drugs across the intestines, the kidneys, and the BBB. Various modulators that inhibit P-gp are often co-administered with other bioactive agents to increase bioavailability. However, use of these compounds is limited by their toxicity. To achieve P-gp inhibition, doses that result in high serum concentrations of the toxic inhibitor are required. Although various approaches have been studied to overcome P-gp mediated drug efflux, P-gp remains a major barrier to bioa-vailability, chemotherapy, and effective permeation of P-gp substrates into the brain and other tissues. Invention Details:
In response to these troublesome efflux issues, UMKC researchers have developed methods of: Converting drugs that are substrates for the P-gp transporter into derivatives not recognized by P-gp as substrates, preferably targeted to and recognized by an influx membrane transporter/receptor (such as a peptide, vitamin or other nutrient trans-porter). The efflux of such derivatives from cel s by the P-gp transporter is thereby eliminated or substantial y reduced while their transport into target cel s by one or more influx transporters/receptors can be effectively enhanced increasing the bioa-vailability of bioactive compounds that are P-gp substrates. Increasing the concentration of bioactive compounds that are P-gp substrates in sanctuary sites of a mammalian subject. Enhancing cel ular delivery of bioactive compounds that are P-gp substrates. Suggested Uses:
For use with various anticancer drugs, anti-HIV drugs, calcium channel drugs, and other drugs which are substrates limited by this efflux transporter. Advantages:
Inhibition of P-gp by various modulators can lead to improved bioavailability of drugs across the intestines, the kidneys, and the blood-brain barrier. Lower toxicity due to less drugs being administered. Please visit our website at: http://www.umkc.edu/ors/ott for a detailed description of this and other technologies. UMKC Office of Technology Transfer

Source: http://ors.umkc.edu/docs/techtransfer/drug-delivery-p-gp-efflux.pdf?sfvrsn=0

Alopecia areata

Alopecia Areata ¿Qué es la alopecia areata? La alopecia areata es un enfermedad frecuente que causa la pérdida del pelo de la cabeza y de otras áreas del cuerpo. Generalmente se empieza en forma de pequeñas placas redondas que pueden ser solitarias o múltiples afectando al cuero cabelludo. ¿A quién afecta la alopecia areata? Según un reciente estudio, la proporción de

pharm.hamptonu.edu

Ayman M. Noreddin, PhD., RPh. Associate Professor and Chair Department of Pharmacy Practice Dr. Noreddin joined the School of Pharmacy at Hampton University in August 2009 as chairperson of the Department of Pharmacy Practice. His ultimate goal is to promote the department’s academic excellence in teaching, service and scholarly activities. Dr. Noreddin has outstanding records of scie

Copyright © 2010-2014 Pdf Medical Search